NIH will fund investigator-initiated multi-site or decentralized clinical trials relevant to its mission, supporting planning and implementation over up to 7 years using a milestone-driven UG3/UH3 grant mechanism.
This grant supports planning and implementing behavioral and social intervention clinical trials related to dental, oral, or craniofacial conditions, with a two-year planning phase (UG3) and potential transition to a five-year clinical trial implementation phase (UH3).
NIH's R21 grant supports early-stage, high-risk clinical trial research with potential for breakthroughs in biomedical, behavioral, or clinical fields.
NIH plans a milestone-driven award supporting planning and early to definitive clinical trials across biomedical and other interventions for up to 7 years; applications are not yet being accepted.
NHLBI plans to fund single-site clinical trials (R61/R33) testing therapeutic, behavioral, or prevention strategies, encouraging innovative designs.